top of page

FOR IMMEDIATE RELEASE

 

Contact:

Glint Pharmaceuticals

617-957-9858

info@glintpharma.com

 

Glint Pharmaceuticals Receives FDA IND Acceptance for Clinical Study for Phase 1/2 Clinical Trial of Antibiotic Drug-Releasing Contact Lens, ACL5

 

Investigation to initiate in Q2 2023 

 

Cambridge, MA – January 31, 2023— Glint Pharmaceuticals (Glint), a clinical-stage biotechnology company focused on developing a next-generation contact lens drug delivery technology, announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate its antibiotic drug delivery contact lens, ACL5. Glint anticipates beginning the investigation in Q2 2023. 

 

Glint plans to perform a Phase 1 Phase 2 clinical trial to evaluate ACL5 (lens is soaked in 5 mg/ml drug solution) as a single agent for the treatment of patients with corneal infection. ACL5 includes moxifloxacin, a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by various susceptible strains of various bacterial organisms. Moxifloxacin will be released over several days to treat bacterial infection and corneal damage. The study will establish safety, tolerability, pharmacokinetics, and infection-fighting properties in patients wearing the drug-eluting contact lenses for a predetermined period of time.

 

“We believe that ACL5 has the potential to improve clinical responses to corneal infection and damage in up to 5 million people in the US and Europe, without the use of daily eye drops,” said Chris Adams, CEO of Glint. “We look forward to collaborating with our clinical partners to launch this trial in the United States in early 2023 and to announce initial results in late 2023."

 

About Glint Pharmaceuticals

 

Glint Pharmaceuticals is developing a patented drug delivery system for the treatment and prevention of ocular infections and disorders. Eye infections and corneal abrasions, glaucoma, post-surgical ocular inflammation, allergic conjunctivitis, and dry eye are examples of disorders to be addressed. More than 40 million Americans are estimated to have ocular surface disease. The patent-protected Glint technology has the potential to enhance therapeutic efficacy and increase patient compliance. Glint has licensed the contact lens technology from the University of Florida

FOR IMMEDIATE RELEASE

 

Contact:

Glint Pharmaceuticals

617-957-9858

info@glintpharma.com

 

Glint Pharmaceuticals to Present at OIS Israel 2022 Ophthalmology Conference 

 

The Glint Drug-Releasing Contact Lens Contains is a Platform Technology for Ocular Therapy  

 

SOMERVILLE, MA – November 10, 2022— Glint Pharmaceuticals to present its drug releasing contact lens technology at the ophthalmology conference, OIS Israel 2022 in Jerusalem, Israel on November 9-10th. OIS Israel is a leading ophthalmology conference where industry leaders and clinicians meet to present new and innovative technologies and clinical results. 

 

The first Glint product is an antibiotic releasing contact lens. The market for an effective and convenient treatment for cornea infection and injury includes more than 10 million patients in the US and EU.  The current standard of care requires the patient to administer antibiotic eye drops on a frequent basis over several days to treat the ocular infection. The Glint lens will eliminate the need for most patients to use the antibiotic eye drops. Replacing the need for patients to apply eye drops will increase compliance and may lead to better therapeutic outcomes. 

 

About Glint

Glint Pharmaceuticals, a Massachusetts company, is developing proprietary drug delivery technology for the treatment and prevention of ocular infections and diseases. Examples of diseases to be treated include eye infections and corneal abrasions, glaucoma, post-surgical ocular inflammation, allergic conjunctivitis, and dry eye. Over 40 million Americans suffer from ocular surface disease. The patented Glint technology has the potential to increase drug efficacy and improve patient compliance. The contact lens technology is licensed to Glint from the University of Florida.

bottom of page